Volume 6, Issue 3 Special Edition, September 2015

Volume 6, Issue 3 Special Edition, September 2015

Index

CONGRESS HIGHLIGHTS

Monitoring deep response in chronic myeloid leukaemia: new methodologies and innovative technologies


Optimizing patient outcomes in CML


When is ponatinib a suitable treatment option for patients with chronic phase CML and how can we optimize the benefit/risk ratio?


Inotuzumab ozogamicin (InO) shows promising efficacy and safety in ALL


Blinatumomab: new hope for patients with relapsed/refractory acute lymphoblastic leukemia

T. Feys


Driver mutations and their evolution in CLL


Venetoclax-rituximab induces deep responses in relapsed CLL


Advances in Acute Myeloid Leukaemia: Increased insights in chemoresistance and first randomised evidence for kinase inhibition


Highlights in Non-Hodgkin’s Lymphoma


Prevention of febrile neutropenia with prophylactic G-CSF improves outcome


Immunotherapy: a new era in the management of lymphoma and multiple myeloma?


Nivolumab is safe and effective in patients with relapsed/refractory lymphoid malignancies and classical Hodgkin lymphoma


Multiple myeloma is different in elderly patients


Adding elotuzumab to standard treatment for multiple myeloma delays disease progression


Carfilzomib-dexamethasone: a new ‘best in class’ in multiple myeloma


Luspatercept increases hemoglobin and decreases the transfusion need in patients with low-, and intermediate-1 myelodysplastic syndrome


JAK2 inhibitor pacritinib significantly benefits patient reported outcomes in myelofibrosis


New treatment options for patients with inadequately controlled polycythemia vera


Management of thrombosis in Paroxysmal Nocturnal Hemoglobinuria


Polyphosphate, a modulator of hemostasis and thrombosis: a novel target for antithrombotic agents?


New genetic variants in GFI1B discovered in patients with bleeding and platelet disorders


Longer acting agents for the treatment of bleeding disorders


X